Appetite suppression often occurs within the first one to two weeks, while measurable weight loss typically starts by week four
These injectable medications mimic a natural hormone called glucagon-like peptide-1 (GLP-1), which helps regulate your appetite, blood sugar levels, and digestion
(NIDDK) I also see a second misconception: that success on these medications is purely about eating less. In reality, the reason many patients do better with GLP-1-based treatment is that these medications can change the biology driving overeating, poor fullness signaling, and dysregulated blood sugar
Eligibility in India generally means a BMI of 2730 with a metabolic complication (such as PCOS, fatty liver, or prediabetes) or a BMI above 30, alongside uncontrolled Type 2 diabetes, abdominal obesity, or strong family history of metabolic disease
Daily oral orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with weight reduction [30] [31], offering potential advantages regarding administration route and patient convenience
